



January 2, 2013

## BioCryst to Present at J.P. Morgan Healthcare Conference

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)-- [BioCryst Pharmaceuticals, Inc.](http://www.biocryst.com) (NASDAQ:BCRX) today announced that Jon Stonehouse, President and Chief Executive Officer of BioCryst is scheduled to present and provide a corporate summary and update regarding the Company at the 31<sup>st</sup> annual J.P. Morgan Healthcare Conference in San Francisco on Thursday, January 10, 2012 at 10:30 a.m. Pacific Time.

Links to a live audio webcast and replay of the presentation may be accessed on the BioCryst website events page at <http://investor.shareholder.com/biocryst/events.cfm>.

### About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals designs, optimizes and develops novel small molecule drugs that block key enzymes involved in infectious and inflammatory diseases, with the goal of addressing unmet medical needs of patients and physicians. BioCryst currently has two late-stage development programs: peramivir, a viral neuraminidase inhibitor for the treatment of influenza, and ulodesine, a purine nucleoside phosphorylase (PNP) inhibitor for the treatment of gout. In addition, BioCryst has several early-stage programs: BCX4161 and a next generation oral inhibitor of plasma kallikrein for hereditary angioedema, BCX4430, a broad spectrum antiviral for hemorrhagic fevers, and BCX5191, a nucleoside analog inhibitor of HCV RNA polymerase (NS5B) for hepatitis C. For more information, please visit the Company's website at [www.BioCryst.com](http://www.BioCryst.com).

This press release contains forward-looking statements, including statements regarding future results and achievements. These statements involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements to be materially different from any future results, performances or achievements expressed or implied by the forward-looking statements. Please refer to the documents BioCryst files periodically with the SEC and located at <http://investor.shareholder.com/biocryst/sec.cfm>.

BCRXW

BioCryst Pharmaceuticals  
Robert Bennett, 919-859-7910

Source: BioCryst Pharmaceuticals, Inc.

News Provided by Acquire Media